▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1043 by analyst upside · 2026-09-26
PLRX
Pliant Therapeutics, Inc.
Healthcare · Market Cap $67M · P/E 0x
ANALYST PRICE TARGET
+85.2%
implied upside to consensus target
Current Price $1.08
Consensus Target $2.0
Bull Target $2.0
Bear Target $2.0
Analysts Covering 1
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
1
Sell
0
52-Week Low $1.02
52-Week High $1.95
YTD Return -13.6%
FUNDAMENTALS
Market Cap $67M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.02
52-Week High $1.95
Current Price $1.08
Bear Target $2.0
Bull Target $2.0
● Now $1.08 ● Target $2.0
TRADING DATA
Avg Volume 499K
YTD Return -13.6%
Analyst Count 1
Consensus Hold
Upside to Target +85.2%
Last Updated 2026-09-26

ANALYST SUMMARY

Pliant Therapeutics, Inc. (PLRX) is currently trading at $1.08 with a Wall Street consensus price target of $2.0, implying potential upside of 85.2% over the next 12 months. 1 analysts currently cover PLRX, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $2.0, while the most cautious has a target of $2.0.

PLRX operates in the Healthcare sector with a market capitalisation of $67M. The stock is down 13.6% year-to-date and is currently trading near the lower end of its 52-week range of $1.02 – $1.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

DXR +81.7%
Daxor Corporation
$64M · P/E 6.5x · Strong Buy
BSEM +69.1%
BioStem Technologies, Inc.
$74M · P/E 4.7x · Buy
FBIO +119.3%
Fortress Biotech, Inc.
$76M · P/E 0.8x · Buy
ELOX +154.5%
Eloxx Pharmaceuticals, Inc.
$52M · P/E 4.3x · Buy
BTMD +114.1%
biote Corp.
$41M · P/E 8.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PLRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Hold → Hold 2026-03-13 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-03-12 14% win rate (7 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2025-11-07 Building track record
JP Morgan ↓ Downgrade
Neutral → Underweight 2025-10-10 43% win rate (7 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2025-08-08 14% win rate (7 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-03-18 31% win rate (48 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-03-04 31% win rate (48 calls)
Citigroup - Reiterated
Neutral → Neutral 2025-03-04 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
15
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →